WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Thursday, December 8, 2016

Gastroparesis, With Constipation, Common In Parkinson’s Disease

DECEMBER 8, 2016



San Diego—Most patients with Parkinson’s disease experience gastroparesis, a “disturbing” figure that could help explain why many people with the neurologic condition have difficulty taking medication for the illness, researchers have found.
The study used capsule technology to measure motility in patients with Parkinson’s disease at Stanford University and the Parkinson’s Institute, in Sunnyvale, Calif.
“The disturbingly high prevalence and magnitude of gastroparesis seen in this cohort may contribute not only to symptoms—bloating, weight loss—but also to altered pharmacodynamics of Parkinson’s disease medications, resulting in poor drug efficacy,” said Andrew Su, MD, now a gastroenterology fellow at the University of California, Los Angeles, who presented the findings at the 2016 Digestive Disease Week (abstract Mo1594).
Chronic constipation is the single most common gastrointestinal symptom associated with Parkinson’s disease, reported in up to 80% to 90% of patients, Dr. Su said. At the same time, delayed gastric emptying has been shown to be correlated with unpredictability of motor fluctuations in Parkinson’s patients, according to Dr. Su.
The wireless motility capsule is a simple device that is swallowed in the outpatient setting. It is a validated test that can be used to quantify colonic transit time in chronic constipation, but it can also measure transit time in the stomach, small intestine and whole gut, Dr. Su said.
The researchers assessed the prevalence and severity of gastric, small intestinal and colonic transit delay in 26 Parkinson’s patients presenting with constipation and undergoing evaluation with the capsule at the university’s neurogastroenterology and motility center. All patients underwent clinical examination and were off laxatives but were maintained on their neurologic medications, according to the researchers.
Of the 26 studies, 16 (62%) revealed prolonged gastric emptying, three (11%) showed prolonged small bowel transit, 18 (69%) found prolonged colonic transit and 20 (77%) revealed prolonged whole gut transit.
In patients with abnormal gastric emptying times, the mean was 7.8 hours, compared with 2.9 hours in those with normal times and almost twice the upper limit of normal, Dr. Su reported. In patients with prolonged colonic transit, the mean was 81.5 hours, nearly 50 hours longer than patients with normal tests, the researchers found.
Small bowel transit appeared to be preserved in most patients with Parkinson’s disease. However, small intestinal bacterial overgrowth, determined by a lactulose breath test, was observed in 30% of these patients, the researchers reported.
Dr. Su and his colleagues are conducting a prospective study involving more patients, and they will correlate capsule test results with qualitative patient-reported GI and neurologic symptoms. Therapeutic implications of these delayed transit times also should be determined in future research, he said.
Often ‘Hidden in the Neurology Clinic’
Gastroenterologists should be familiar with the association between Parkinson’s and constipation, but many times these patients are “hidden” in the neurology clinic, said Richard McCallum, MD, professor and founding chair of the Department of Internal Medicine at Texas Tech University Health Sciences Center, in El Paso, and an expert in gastroparesis.
“When gastroenterologists see them, the condition can be severe,” Dr. McCallum said. “In fact, these can be some of the worst constipation challenges we see.” Levodopa, the drug commonly used to treat Parkinson’s disease, may slow the transit time, Dr. McCallum said. However, the disease itself also involves the colon and can create transit problems regardless of the medication, he explained.
Indeed, severe constipation can be “an early tip-off” to underlying, undiagnosed Parkinson’s, he said.
In terms of management, “you just have to give [linaclotide (Allergan/Ironwood)], MiraLax and Dulcolax,” he said. “You can get the colon back to normal, but remember there is more to the gut. A slowed stomach often accompanies this condition; l-dopa can cause nausea; and there can be other symptoms in the GI tract.”
—Caroline Helwick
http://www.gastroendonews.com/In-the-News/Article/11-16/Gastroparesis-With-Constipation-Common-In-Parkinson-s-Disease/38523

No comments:

Post a Comment